Contact our breast care nurses 0808 800 6000

Breast Cancer Now media statements

103 results
Media Statement
Response to the Spending Review 2020

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, was deeply concerned by the lack of clarity as to whether funding will be available for medical research charities.

25 Nov 2020

Media Statement
We respond to NHS England breast cancer waiting times: September 2020 and Q2 20/21

Mia Rosenblatt, Associate Director of Policy and Influencing at Breast Cancer Now, commented on NHS England breast cancer waiting times for September 2020 and Q2 20/21.

12 Nov 2020

Media Statement
We respond to a BMJ Study that provides new estimates of breast cancer risks associated with HRT

Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, responded to a BMJ Study which provides new estimates of breast cancer risks associated with HRT.

10 Nov 2020

Media Statement
We respond to news that the pandemic ‘threatens research as early career scientists look to leave’

Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, was deeply concerned that 40% of charity-funded early career scientists have considered leaving research due to COVID-19.

10 Nov 2020

Media Statement
We support recommendations for faster and wider access to innovative cancer treatments

Mia Rosenblatt, Associate Director of Policy and Influencing at Breast Cancer Now, called for recommendations for faster and wider access to innovative cancer treatments.

09 Nov 2020

Media Statement
We welcome SMC approval of adjuvant Kadcyla and atezolizumab with nab-paclitaxel for use on the NHS

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, welcomed the Scottish Medicines Consortium's approval of adjuvant Kadcyla and atezolizumab with nab-paclitaxel, for use on the NHS.

09 Nov 2020

Media Statement
We respond to ‘plasmaMATCH’ trial that uses blood test to match women with breast cancer to a range of precision treatments

Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said the plasmaMATCH trial was an important development in the field of liquid biopsies.

11 Sept 2020